INTRODUCTION
are the largest family of transmembrane receptors in humans, and they serve as critical regulators of most aspects of physiology. As a consequence of their profound biological importance, GPCRs have become the most successful target class for therapeutic drug development, and GPCR-targeted drugs include most treatments for cardiovascular, neuropsychiatric, and metabolic diseases. GPCR research has seen major advances in recent years, particularly in terms of studies of receptor structure, dynamics, and pharmacology. Nonetheless, many major aspects of GPCR signaling remain incompletely characterized, and it has become increasingly clear that GPCRs possess an unexpectedly rich and complex signaling biology that is only beginning to be fully understood.
The classical paradigm for GPCR signaling through G proteins was elucidated decades ago (Gilman, 1995) and is now relatively well understood. Upon binding an activating ligand (agonist), a GPCR undergoes conformational changes and catalyzes the exchange of GDP for GTP in Ga subunits of G protein heterotrimers. Activated G proteins subsequently activate or inhibit downstream effectors like adenylyl cyclase, leading to a plethora of cellular responses. Shortly following G protein activation, GPCRs are phosphorylated by GPCR kinases (GRKs), leading to the recruitment of b-arrestins and consequent endocytosis. Initially, b-arrestins were considered to be nothing more than silencers of GPCR signaling, but it is now clear that GPCR activation results in G-protein-independent signaling mediated primarily by b-arrestins in addition to G protein-mediated responses (Lefkowitz, 2013) .
Existing GPCR signaling assays are informative but suffer from limitations, including single pathway readout, limited time resolution, and overexpression or modification of the very effectors they aim to study. Moreover, most signaling assays report on events far downstream of ligand-mediated changes in receptor activity. In addition, studies of GPCR signaling are complicated by the fact that many ligands exhibit varying degrees of ''biased'' signaling, preferentially activating some pathways more than others (e.g., activation of G proteins, but not b-arrestins). The phenomenon of biased signaling holds the potential for transformative innovations in medicine, as it allows pharmacological separation of G protein signaling from b-arrestin signaling, thereby achieving clinical benefit with greatly reduced side effects . Despite this, the molecular details underlying biased signaling remain poorly characterized, and even quantification of signaling bias has been intractable due to limitations with existing methods.
To address these challenges, we sought to develop a method that allows parallel quantification of GPCR interactions with all effectors within a native cellular environment at endogenous expression levels. One candidate approach to achieve this was fusion to a promiscuous biotin ligase (Roux et al., 2012) , but the slow labeling kinetics made this approach unsuitable for studying GPCR activation with high temporal resolution-an essential requirement in light of the fact that most GPCRs regulate physiological responses on timescales ranging from seconds to minutes. In contrast, the engineered ascorbate peroxidase APEX2 rapidly produces short-lived (< 1 ms) biotinphenoxy radicals that have a limited ($20 nm) labeling radius, thereby overcoming these problems (Hung et al., 2016) . We reasoned that combining GPCR-APEX2 fusion with quantitative mass spectrometry could allow observation and quantification of GPCR-proximal proteins with high temporal resolution. To enable accurate relative quantification of protein abundance, we chose to use isobaric tandem mass tags to label samples (Thompson et al., 2003) . This approach allows all labeled samples to be pooled and analyzed in a single mass spectrometry experiment so that relative abundances of thousands of proteins from up to ten different samples are measured in a highly reproducible and quantitative manner.
To test the suitability of APEX2 as a potential tool to study GPCR signaling, we chose the angiotensin II type 1 receptor (AT1R) as our model. The AT1R is one of the principal regulators of blood pressure in humans and is the target of widely used antihypertensive drugs, including losartan (Cozaar), irbesartan (Avapro), telmisartan (Micardis), and several others. In addition to its profound importance in human health, the AT1R is one of the most extensively studied model GPCRs in terms of pharmacology and cell biology, and strongly b-arrestin biased ligands such as TRV027 are readily available and well characterized (Strachan et al., 2014; Violin et al., 2010) . The AT1R robustly internalizes for an extended period following agonist treatment, making it a prototypical ''class B'' receptor with respect to its internalization properties (Oakley et al., 2000) . Taken together, these features make the AT1R an ideal system for exploring both receptor internalization and signaling bias.
RESULTS

Design and Assessment of GPCR-APEX Platform
We envisioned that the AT1R fused to APEX2 at its carboxy terminus (C terminus) would offer a straightforward approach to performing proximity labeling ( Figure 1A ). The C terminus of AT1R is predicted to be intrinsically unstructured and is not resolved in a recent crystal structure of the receptor bound to an antagonist (Zhang et al., 2015) , indicating that fusion to APEX2 enzyme at its C terminus is unlikely to alter its functional properties. Indeed, the APEX2 fusion receptor showed signaling and internalization properties similar to those of the wild-type (WT) receptor (Figures S1A and S1B). AT1R-APEX differed significantly from the WT receptor only in its expression level, which was reduced roughly 4-fold relative to the WT receptor.
We first sought to assess proximity labeling efficiency and the reproducibility of protein quantification. To perform proximity labeling experiments, HEK293T cells stably expressing AT1R-APEX were pre-incubated in medium containing biotin-phenol (the total length of incubation in biotin-phenol was 1 hr before H 2 O 2 treatment), then treated with agonist (angiotensin II) or antagonist (losartan) at either 1 or 20 min before 1 min hydrogen peroxide incubation to start labeling. Similarly, samples without ligand treatment or hydrogen peroxide treatment were prepared to assess changes in biotinylated proteins upon ligand treatment and endogenous biotinylation level, respectively. Biotin labeling was quenched immediately after 1 min using the described quench buffer (Hung et al., 2016) . Afterward, biotinylated proteins were enriched by denaturing streptavidin affinity purification, digested into tryptic peptides, labeled with isobaric tandem mass tags (TMT), fractionated by alkaline reversed phase chromatography, and analyzed by triple stage mass spectrometry (TMT SPS MS 3 ; Figure 1B ). Quantification by SPS MS 3 rather than applying conventional tandem mass spectrometry (MS 2 ) has the advantage of reducing signal ratio distortion and enhancing the accuracy of peptide (and, by inference, protein) quantification (McAlister et al., 2014; Paulo et al., 2016b; Ting et al., 2011) .
Western blotting confirmed robust biotinylation and revealed a different spectrum of labeled proteins in agonist-and antagonist-treated samples (Figure 2A ). By mass spectrometry analysis, 8,281 peptides were quantified, representing a total of 1,242 proteins. For the four independent biological replicate pairs, isobaric tag-based measurements of protein abundance showed excellent correlation (R 2 > 0.97), indicating that the procedure allows highly reproducible protein quantification regardless of experimental conditions . It is important to note that in these experiments, a lack of observation of a given protein does not imply lack of association. Peptides may not be detected due to many factors, including inherent unsuitability for mass spectrometry, steric obstruction of labeling, or lack of suitable reactive moieties in the protein sequence. Nonetheless, despite these caveats, a broad collection of GPCR signaling effectors were observed, including b-arrestin 2 and a variety of G proteins, among many others. One of the fundamental questions in GPCR signaling is whether GPCRs co-localize with G protein subunits in specific micro-domains or lipid rafts within the cell membrane to facilitate rapid signal transduction (Oates and Watts, 2011) . However, characterization of such micro-domains has been challenging due to difficulties in their biochemical manipulation. To characterize the native local milieu of the AT1R in cells, we used AT1R-APEX to identify and quantify proteins within the APEX Figure 1 . Design and Experiment Procedure of Proximity Labeling by AT1R-APEX (A) Schematic of APEX2-mediated protein labeling. The angiotensin receptor (AT1R) fused to APEX2 at its C terminus via a glycine-serine linker biotinylates proteins in proximity (< 20 nm) to the receptor in an unbiased manner, allowing identification and quantification of interactions between the receptor and its effectors at distinct time points after ligand treatment. (B) Proximity labeling and mass spectrometric analysis workflow for AT1R-APEX. Four different pairs of biological replicates were prepared to assess reproducibility of labeling and proteomic analysis in both short and long time points for agonist or antagonist treatment. Biotin-labeled proteins were purified by TCA precipitation followed by denaturing streptavidin pull-down and tandem mass tag labeling to allow quantitative mass spectrometric analysis of ten different samples in parallel. See also Figure S1 . labeling radius. By comparing the abundance of peptides derived from AT1R-APEX cells with hydrogen peroxide treatment to those without (background), we could confirm that heterotrimeric G proteins were strongly enriched in the absence of ligand treatment, with the AT1R signal transducer Ga q showing the strongest enrichment among G proteins ( Figure 2C ). However, other Ga subunits, including those that do not couple with AT1R, were also strongly enriched, supporting the idea that GPCRs co-localize with multiple components of their signaling machinery in lipid rafts or other microdomains. b-arrestin 2 was also observed and quantified in both control and labeled samples, but unlike G proteins, it showed relatively low enrichment in the absence of ligand treatment, consistent with its cytosolic localization prior to receptor activation.
These data additionally allowed straightforward assessment of the effects of the antagonist losartan relative to untreated samples. Interestingly, no strongly different enrichment is seen for any of the 1,242 proteins measured, including G proteins and b-arrestins ( Figure 2D ). This suggests that losartan acts effectively as a neutral antagonist in these conditions, with no significant effect on receptor-effector interactions or subcellular localization.
Comparison of cells treated with the endogenous agonist angiotensin II to the untreated control cells was more revealing. At the two time points measured (2 min and 21 min), a diverse population of proteins showed strong enrichment in the presence of agonist, including known effectors and regulators of receptor internalization: b-arrestin 2, AP-2, clathrin, FCHo protein, and intersectins ( Figure 2E ). Importantly, the isobaric tagging approach allows simultaneous quantification of all proteins measured rather than just a select subset. Hence, statistical analysis of relative enrichment between agonist-treated and antagonist-treated samples was possible across all proteins ( Figure 2F ). The analysis highlighted known effectors and components of the endocytosis machinery that had the largest and most significant divergence between samples. These data suggest that even in the absence of prior knowledge in signaling effectors, it may be possible to identify signal transduction components using receptor-APEX fusion together with isobaric labeling. Full experimental data are reported in Table S1 .
Time-Resolved AT1R-APEX
We next sought to extend these techniques to address a key limitation of most existing GPCR signaling assays: time resolution. Given the highly dynamic nature of GPCR signaling, the kinetics of signaling and receptor trafficking are of critical importance, but are difficult to measure using most conventional GPCR signaling assays. Using a modified APEX labeling protocol (Figure 3A) , we tracked AT1R interactions at ten different time points, including 10 s intervals for the first 50 s, as well as sparser sampling at time points up to 30 min. One sample with no ligand treatment was included to serve as a reference for assessing relative peptide enrichment at other time points.
The time-resolved analysis allowed tracking of AT1R proximity kinetics for 1,034 proteins. Known interaction partners, including G proteins and b-arrestin 2, were readily observed and tracked. At its peak, b-arrestin 2 reached levels that were 27-fold higher than in the agonist-free state. b-arrestin 2 association kinetics were almost identical to those for known clathrin-mediated endocytosis components such as AP-2, PICALM, and clathrin itself ( Figure S3A) . Surprisingly, b-arrestin enrichment level dropped after its peak at 180 s, while endosomal markers, including Rab5 and Rab7, persisted, indicating that arrestin at least partially dissociates from the receptor following clathrinmediated endocytosis ( Figure 3B ). This observation contrasts with the current view of b-arrestin-class B GPCR interaction that the arrestin-receptor complex remains stable in endosomes (Pierce and Lefkowitz, 2001) .
A similar kinetic analysis for heterotrimeric G protein a subunits showed an immediate drop in G protein labeling in the first 10 s. This was followed by a gradual rise and subsequent decline over the first minute, with peak labeling at 50 s. In light of recent reports that endosomal signaling may be important for some GPCRs (Irannejad et al., 2013; Thomsen et al., 2016) , we sought to examine whether G proteins are internalized together with the AT1R. In fact, receptor-proximal G protein levels showed a significant decrease coincident with the arrival of arrestin and the clathrin-mediated endocytosis machinery ( Figure 3C ). This indicates that endocytosis selectively internalizes the receptor and largely sequesters it away from the G proteins of all classes observed. These results do not exclude the possibility of endosomal signaling entirely, however, as low levels of G protein from each class were still present following internalization.
In addition, GPCR-APEX provides a platform for tracking endocytosis and subcellular localization over longer timescales. As discussed above, recruitment of the clathrin machinery closely paralleled arrestin recruitment. Shortly thereafter, endosomal markers, including Rab5, Rab7, and transferrin receptor, all increased in enrichment. At later time points, receptor interaction with retromer complex proteins, including VPS29 and SNX1, was observed, beginning around 10 min. A portion of the receptor population also appears to enter lysosomes, indicated by the enrichment of LAMP1 at 10 min and 30 min time points (Figures 3B and 3E) . Full quantification data for all 1,034 proteins measured at each time point are included in Table S2 . See also Figure S2 and Table S1 .
Kinetics of AT1R Response to a b-Arrestin-Biased Agonist We next sought to extend this technique to examine the consequences of AT1R activation by the biased agonist TRV027. While the endogenous agonist angiotensin II is known to activate both G q and b-arrestin-mediated signaling, TRV027 was developed and designed to preferentially activate b-arrestin (Violin et al., 2010) . This b-arrestin-biased signaling is thought to account for the fact that TRV027 administration both decreases blood pressure and increases cardiac output. To assess the signaling and internalization processes induced by TRV027, we employed AT1R-APEX in the same time-resolved approach described above.
In general, TRV027 led to receptor internalization on a timescale similar to that induced by angiotensin II. For both agonists, b-arrestin was robustly recruited, beginning around 50 s, and reached the maximum enrichment level at 180 s before declining slowly thereafter. Clathrin light and heavy chains, as well as AP-2 subunits, were similarly enriched at 180 s, showing that receptor internalization kinetics and the recruitment of proteins involved See also Figure S3 and Table S2 .
are mostly independent of ligand bias (Figures 4A and S3B) . As with angiotensin II treatment, b-arrestin 2 level declined over 5-fold following the arrival of the endosomal markers Rab5 and Rab7, indicating that arrestin is released from the receptor at later stages of endocytosis. Similar to AT1R experiments with other ligands, in TRV027 treated samples, many Ga subunits were quantified over all time points. This includes both G proteins that couple strongly (Ga 11 and Ga q ) and those that couple less robustly or not at all (Ga i1 , Ga i2 , Ga i3 , Ga s , Ga 13 , Ga o1 ) with AT1R. A detailed analysis of G protein kinetics revealed more similarities and differences in pharmacology between angiotensin II and TRV027. When cells were treated with angiotensin II, G protein labeling efficiency showed an immediate drop followed by a slow rise and then a decrease starting at the 50 s time point ( Figure 3D ). TRV027-treated cells showed a more moderate decline in all G protein enrichments starting from 10 s until the 30 s time point, after which labeling efficiency recovered at 50 s ( Figure 4C ). However, decrease in enrichment at early time points (0-50 s) is challenging to interpret, since the labeling events that occur within one time point also occur in the subsequent time points. G protein labeling efficiency stayed static afterward and dropped thereafter as the activated receptor internalized via clathrinmediated endocytosis (Figures 4B and 4C) . Later stages of the receptor internalization process appear largely similar between angiotensin II and TRV027-treated samples, with retromer components identified and quantified for both ligands (Figure 4A and 4D) . See also Figure S3 and Table S2 . (A) Internalization kinetics of b2AR (class A GPCR) are different from those of AT1R (class B GPCR). b-arrestin is recruited with the peak at 180 s, but clathrin recruitment is delayed to 600 s. Also, Rab5 enrichment peak is at 600 s, indicating that arrestin-receptor complex formation and endosomal entry do not occur simultaneously. Late endosomal marker Rab7 and lysosomal marker LAMP1 enrichment peaks appear afterward. (B) Enrichment pattern heatmap of selected proteins. Each protein's enrichment level across different time points is normalized to its maximum enrichment signal.
Receptor internalization results in a loss of receptor-proximal EBP50, ARF6, and GRK6. However, ARF6 activator GIT1, GRK2, and adenylyl cyclase 3 (ADCY3) enrichment levels remained constant. Adenylyl cyclases 6 and 9 (ADCY6 and ADCY9) show moderate decrease in enrichment levels upon receptor internalization. However, a significant portion of these proteins remained in proximity of b2AR (> 40% of maximum enrichment levels). Gas and adenylyl cyclase signaling attenuator caveolin-1 (CAV1) and retromer component VPS29 highly enrich during internalization (600 s). Heatmap of b2AR S246 phosphorylation level shows a drop in phosphorylation commensurate with receptor internalization.
b2AR-APEX for Elucidating b 2 Adrenergic Receptor Signaling A key question surrounding the GPCR-APEX technique presented here is its potential generalizability. In principle, fusion of APEX2 to the receptor C terminus should allow time-resolved multidimensional tracking of interactions for virtually any GPCR.
To test this, we chose to extend our study to the human b 2 adrenergic receptor (b2AR). This receptor is one of the most extensively investigated GPCRs in terms of its structure, conformational dynamics, and cell biology. It is the target of b agonists used in the treatment of asthma and other respiratory conditions, including the widely used drugs albuterol and salmeterol. The b2AR is also the prototypical ''class A'' GPCR with respect to its internalization behavior (i.e., it internalizes and is recycled rapidly; Oakley et al., 2000) . In contrast to the AT1R, the b2AR is rapidly recycled to the plasma membrane following its stimulation with agonists. In addition, internalized b2AR has been suggested to contribute to cell signaling through its persistent activation of G proteins and adenylyl cyclase in endosomes (Irannejad et al., 2013) . First, we designed a b2AR-APEX fusion construct in which the proximity labeling enzyme is fused to the receptor at its C terminus, as for the AT1R. Then, we confirmed that b2AR-APEX has signaling properties similar to those of the WT receptor (Figure S4A) , and we assessed its expression level, along with that of AT1R-APEX ( Figure S4B ). As with AT1R-APEX, we generated a HEK293T cell line stably expressing the b2AR-APEX and treated the cells with the high-affinity full agonist BI167107 for varying time intervals ( Figure S4C ). We selected BI167107 rather than a conventional agonist such as isoproterenol due to the generation of biotin-phenoxy radicals by APEX for proximity labeling. Catecholamines like isoproterenol are prone to oxidation by radicals, potentially complicating or precluding measurements at short time points in which ligands are treated after APEX starts generating biotin-phenoxy radicals. As with the AT1R, we chose to perform 10 s sampling for early events, and then sparser sampling extending to 30 min. In total, 48,392 peptides were observed, accounting for 3,598 unique proteins that could be tracked throughout the time course (Table S3) .
As in the case of the AT1R, receptor internalization could be tracked by following endosomal and lysosomal markers. Arrestin with AP-2 and then clathrin appeared in sequence, as did Rab5 and Rab7, followed by LAMP1 ( Figures 5A and S5A ). Taken together, these data suggest that the receptor ultimately reaches the lysosome, although retromer complex components such as VPS29 are also robustly recruited at late time points and may salvage some of the receptor for recycling. However, an important caveat is that the C-terminal fusion of APEX to the b2AR may disrupt endocytic retrieval and recycling by the PDZ domain protein EBP50 (Cao et al., 1999) . EBP50 is in fact observed as a receptor-proximal protein, but is depleted commensurate with receptor internalization ( Figure 5B) .
Interestingly, b2AR-APEX was able to capture differences in internalization kinetics of b2AR from AT1R. Robust b-arrestin 2 recruitment with its maximal enrichment at 180 s was observed for both receptors. However, maximum or near-maximum enrichment peaks for clathrin and Rab5 that were at 180 s for AT1R all shifted to the 600 s time point for b2AR. For both GPCRs, the late endosomal marker Rab7 showed similar maximum or near-maximum enrichment at 600 s ( Figures 3B  and 5A ). b-arrestin 2 enrichment level dropped after internalization, in agreement with the reported features of the b-arrestin-GPCR complex for class A receptors (Pierce and Lefkowitz, 2001 ). In addition, ADP-ribosylation factor 6 (ARF6) and its ARF GTPase-activating protein GIT1 that orchestrate b2AR internalization were quantified: ARF6 levels stayed constant until they dropped more than 4-fold upon internalization, while GIT1 levels remained static through all time points, as shown in Fig- ure 5B (Claing et al., 2001) . Lastly, caveolin-1 (CAV1), which has been suggested to attenuate Gs and adenylyl cyclase signaling by assisting G protein separation from GPCRs (Allen et al., 2009) , increased in enrichment starting at 180 s until its maximum at 600 s.
As for AT1R-APEX, b2AR-APEX analysis revealed a collection of G protein a subunits that were highly enriched relative to background at the 0 s (untreated) time point: Ga s , Ga i2 , Ga q , and Ga 11 were over 50-fold enriched with respect to the background (Figure 5C ). Again, b-arrestin 2 showed relatively low enrichment at the ligand-free state. Quantified adenylyl cyclases (ADCY3, ADCY6, and ADCY9) were all highly enriched over the background, suggesting that the b2AR is likely in proximity of these proteins, even prior to ligand stimulation. Previous work using receptor G protein fusions has suggested a possible direct association between the b2AR and adenylyl cyclases, consistent with this observation (Seifert et al., 2002) , although the APEX technique cannot distinguish between direct and indirect interactions. As in the case of the AT1R, these observations support the idea that GPCRs co-localize with the signaling machinery in lipid rafts or other micro-domains prior to activation.
In comparison to AT1R experiments, many more known signaling effectors were detected and quantified in the b2AR experiment. These include the GPCR kinases GRK2 and GRK6 ( Figures 5A and 5B) , which selectively phosphorylate activated GPCRs, a prerequisite for efficient b-arrestin recruitment (Pitcher et al., 1998) . In our experiments, GRK6 was recruited to the receptor before b-arrestin, with an enrichment level peaking at (C) Fold enrichment of detected G protein subunits, b-arrestin 2, and adenylyl cyclases prior to ligand treatment. Fold enrichment in each case is relative to levels in control samples that are not treated with hydrogen peroxide (background). b-arrestin 2 is included as a reference to assess significant enrichment levels over background. (D) Heatmap of all G protein subunits detected shows that almost all G proteins are excluded from endosomes, regardless of their subtypes. (E) b2AR signaling assay to examine LMBRD2 knockdown. HEK293T cells transfected with LMBRD2 siRNA showed a statistically significant difference (decrease) in EC 50 in comparison to control siRNA-transfected cells (p < 0.0001). Data points for ligand-free cells are not shown. All measurements were performed in triplicate, and data are representative of three independent experiments. Data shown as means ± SEM, with EC 50 values reported as LogEC 50 ± 95% confidence interval for the experiment shown here. See also Figure S4 , Figure S5 , and Table S3. 30 s and then declining thereafter. In contrast, GRK2 levels peaked earlier at 20 s and showed relatively little decline at subsequent time points ( Figure 5B) . As in the case of the AT1R, kinetic analysis revealed that G protein labeling falls coincident with the arrival of endosomal markers such as Rab5, suggesting that relatively little G protein is internalized with the receptor to sustain signaling ( Figure 5D ). Unlike AT1R, however, b2AR-APEX does not show any significant decrease in G protein subunit labeling immediately (< 20 s) upon agonist binding (Figure S5B ). Like G proteins, GRK6 levels decreased upon receptor internalization, falling more than 5-fold from peak levels. In contrast, adenylyl cyclase 3 showed a far more modest decline (< 40% from the peak to the lowest point), indicating that a significant fraction of this protein co-internalized with the b2AR, even as the receptor separates from G protein subunits ( Figure 5B ). In addition to revealing kinetics of protein association, our experiments also allowed tracking of one post-translational modification: phosphorylation of Ser246. The ratio of phosphorylated to non-phosphorylated peptides remained static in early time points, but dropped coincident with receptor internalization as shown in Figure 5B .
Many of the proteins quantified in time course experiments that clustered in the kinetic profiling with known signaling components, like b-arrestin 2, were largely uncharacterized not only in relation to GPCR biology, but also in any context. This was surprising, since the biology of the AT1R and b2AR have been studied for decades. To see the potential of GPCR-APEX technique in discovering novel modulators of GPCR signaling, we examined the functional role of one of these proteins, LMBRD2, with respect to receptor signaling.
LMBRD2 is predicted to be a nine-pass transmembrane protein and was identified in both AT1R and b2AR time course experiments. Its biology is, to our knowledge, entirely uncharacterized in any context. The protein has relatively low enrichment level prior to agonist treatment, but it is robustly recruited and reached maximum enrichment at 180 s and clustered with b-arrestin 2 in AT1R experiments ( Figure S3B ). In the b2AR time course experiment, it showed delayed maximum enrichment at 600 s and recruitment kinetics similar to early endosomal marker Rab5 ( Figure 5D ). We hypothesized that LMBRD2 may have a role in receptor internalization. To examine functional association between LMBRD2 and b2AR, we performed a b2AR G protein signaling assay with HEK293T cells transfected either with a LMBRD2-targeting siRNA or a control siRNA. LMBRD2 knockdown resulted in roughly a 7-fold potentiation of signaling in response to the full-agonist isoproterenol ( Figures  5E and S5C) . Hence, GPCR-APEX not only allows quantitative tracking of known effectors and regulators, but also holds the potential to enable the discovery of novel mediators of GPCR signaling.
Finally, we investigated the possibility of interactions between the b2AR and other GPCRs. There is evidence suggesting that receptor oligomerization may be important for some GPCRs (Gomes et al., 2016) . Hence, we sought to assess whether there are other seven-pass transmembrane receptors proximal to the b2AR in a native cellular environment. In total, 16 different seven transmembrane receptors were biotin-labeled and identified by b2AR-APEX: proteinase-activated receptor 2 (F2RL1), frizzled receptors (FZD3, FZD6, FZD7, and FZD8), retinoic acid-inducible receptors (GPRC5A and GPRC5C), an adhesion receptor (GPR126), and several others (GPR98, GPR107, GPR125, GPR180, CELSR1, CELSR2, LGR4, and LGR5; Figure S5D ). Receptor enrichment levels remained constant throughout all time points for most of these proteins, indicating that the receptors largely remain associated with the activated receptor even upon internalization. In AT1R time course experiments, GPRC5A and GPRC5C were also detected through all time points. As in the case of the b2AR-associated receptors, GPRC5A and GPRC5C co-internalized with AT1R ( Figures S5F and S5G) . While the functional implications of this finding remain unknown, these results suggest that GPCR-APEX may also be a useful tool for the interrogation of GPCR interactions with other membrane proteins.
DISCUSSION
The GPCR structural biology revolution has reinvigorated GPCR drug discovery and opened the door to fundamentally new approaches to GPCR modulation, including discovery and design of biased ligands with improved medical potential (Manglik et al., 2016) . Despite these transformative innovations in GPCR structure and pharmacology, methods for tracking and quantifying GPCR signaling and internalization have not seen commensurate advances to elucidate remaining questions such as the extent and role of endosomal signaling, the collection of receptor-proximal proteins at baseline, and the similarities and differences of class A and class B GPCR internalization processes. Here, we showed that a new approach using GPCR-APEX fusion combined with isobaric peptide labeling enables massively parallel, time-resolved, and quantitative analysis of GPCR interactions to answer multiple important questions through a single experimental procedure.
The classical view of GPCR-mediated G protein signaling is that stimulated receptors desensitize upon internalization to downregulate signaling and return to the cell membrane after disappearance of stimulus (agonist). Recent reports of endosomal G protein signaling have challenged this view, suggesting that receptors may continue to signal, even after endocytosis. However, the relative extent to which G proteins internalize with receptors has been difficult to assess quantitatively. AT1R-APEX and b2AR-APEX time course experiments provide a solution to this problem, revealing that almost all G proteins are separated from activated receptors during internalization. This suggests that endocytosis selectively sequesters receptors away from G proteins and allows only a small amount of G proteins to internalize together with the receptor. Surprisingly, however, adenylyl cyclase 3 labeling remains high following b2AR endocytosis, indicating that a significant fraction of this effector is endocytosed together with the receptor.
In addition, analysis of AT1R-APEX and b2AR-APEX in their ligand-free state provides insights into the local milieu of GPCRs in cell membrane. Pre-association between GPCRs and G proteins in lipid rafts has long been proposed, but it has been challenging to prove because of difficulties in isolating and identifying components of lipid rafts in a reproducible manner. GPCR-APEX provides a means to address the issue by labeling receptor proximal proteins in living cells. Both AT1R-APEX and b2AR-APEX confirmed the presence of a variety of G alpha subunits in the vicinity of GPCRs even before ligand-treatment, confirming their co-localizations. In addition, lipid raft marker flotillins (FLOT1 and FLOT2) were labeled and detected by both receptors, as was another raft marker, caveolin-1 (Figures 5B, S5E , and S5G). Caveolin-1 enrichment level increased upon stimulation and reached peak at 600 s, closely paralleling the drop in G protein enrichment levels. An additional observation is that several seven transmembrane receptors co-localized with AT1R and b2AR and co-internalized with the activated receptors. While the biological significance of this observation remains unknown, the fact that receptor-receptor associations can be tracked opens the door to quantification of GPCR heteromerization in cells.
GPCR-APEX also allowed discrimination of internalization kinetics between prototypical class A and B GPCRs (b2AR and AT1R, respectively). In the case of AT1R, maximal recruitment of b-arrestin 2 was accompanied by peak enrichment of clathrin and Rab5, indicating that the receptor enters the endosome as soon as the receptor-arrestin complex forms ( Figure 3B ). Similar robust recruitment of b-arrestin 2 at 180 s was observed for b2AR ( Figure 5A ). However, clathrin and Rab5 showed delayed maximum enrichment at 600 s, suggesting that the receptor enters endosomes after the receptor-arrestin complex at least partially dissociates. Intriguingly, AT1R-APEX revealed that the receptor-arrestin complex for class B GPCR upon endosomal entry is not as stable as previously thought.
In addition to quantifying GPCR interaction kinetics, GPCR-APEX allowed analysis of one of the receptor's post-translational modifications. For b2AR, Ser246 is located near the beginning of the unstructured third intracellular loop, a region of the receptor which is important for G protein coupling and other aspects of receptor signaling but is disordered in the crystal structure of the b2AR-Gs heterotrimer complex (Rasmussen et al., 2011) . Of all previously identified b2AR phosphorylation sites, Ser246 is reported as the only site that decreases in phosphorylation level upon agonist-mediated stimulation, while other sites, including Ser355 and Ser356, are phosphorylated by GRKs upon receptor activation (Nobles et al., 2011) . Although a biological role for Ser246 phosphorylation has not yet been described, its relative phosphorylation levels show clear decrease coincident with receptor internalization. It is important to note, however, that the observation of this peptide was largely coincidental because our protocol was not designed to enrich for phosphopeptides. Nonetheless, this observation shows that it is possible to simultaneously perform time-resolved tracking of both protein-protein interactions, as well as receptor post-translational modifications.
Finally, a key value of the proteomics data generated by GPCR-APEX lies in the kinetic profiles of the thousands of receptor-proximal proteins that are detected and quantified. Due to the nature of proximity labeling, the data necessarily include many bystander proteins that do not functionally associate with the GPCR but are in the same subcellular locale. Nonetheless, statistical pairwise comparison of agonist-treated and untreated samples ( Figure 2F ) showed that known effectors are highly enriched in agonist-treated samples, indicating that receptor-APEX may be useful in general to identify new signaling components in poorly understood systems, even without prior information. Even in the case of the AT1R and b2AR, which have been studied for decades, GPCR-APEX allowed identification and characterization of LMBRD2 as a novel modulator of signaling. Moreover, GPCR-APEX allowed direct quantification of the extent to which G proteins, GRKs, and arrestins interact with the receptor as a function of time. Of particular note, our results show that in the conditions tested, receptors are largely sequestered away from heterotrimeric G proteins upon internalization, while at least one downstream effector, adenylyl cyclase 3, internalizes with the b2AR.
In principle, APEX-fusion with tandem mass tag labeling should be broadly applicable to the kinetic monitoring of virtually any signal transduction protein such as non-GPCR receptors, b-arrestins, or heterotrimeric G proteins. Overall, GPCR-APEX provides a powerful new platform for quantitative analysis of GPCR signaling, allowing parallel time-resolved measurement of hundreds to thousands of protein-protein interactions and revealing new aspects of GPCR signaling biology.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Flp-In T-REx 293 Cell Line purchased from Thermo Fisher Scientific was used for all proximity labeling experiments. Unless noted otherwise, cells were grown at 37 C and 5% CO 2 in DMEM with 4.5 g/L glucose and L-glutamine, no pyruvate (VWR) supplemented with 10% FBS (USA scientific), 10 mg/mL Blasticidin (Invivogen), and 10 mg/mL Gentamicin (VWR). Prior to stable transfection, cell medium was supplemented with 100 mg/mL Zeocin (Thermo Fisher Scientific). All stable cell lines were maintained in medium supplemented with 100 mg/mL Hygromycin B Gold (Invivogen) to maintain selection pressure.
METHOD DETAILS
Design and cloning of GPCR-APEX constructs pcDNA3.1/zeo/TO plasmid encoding angiotensin II type 1 receptor (AT1R) was a gift from the Lefkowitz lab (Duke University) and was used to PCR-amplify AT1R gene used for the study. b2 adrenergic receptor gene (b2AR) was PCR-amplified from the Roth Lab PRESTO-Tango GPCR Kit (Addgene). APEX2 DNA was PCR-amplified from pcDNA3 APEX2-NES, which was a gift from Alice Ting (Addgene). Each GPCR-APEX fusion protein has a C-terminal 8-residue glycine-serine linker (GGSSGGSS), followed by APEX2. b2AR-APEX also includes a Protein C affinity tag (EDQVDPRLIDGK) at the C terminus of APEX2. All DNA constructs were cloned into pcDNA5/FRT/TO plasmid for mammalian expression (Invitrogen).
Preparation of stable cell lines for proximity labeling experiments
Flp-In T-REx293 Cell were seeded in 6-well plates in complete medium without zeocin and were grown until 80%-90% confluency, at which point transfection was performed using Lipofectamine 2000 (Thermo Fisher Scientific). Plasmid encoding GPCR-APEX was co-transfected with pOG44 Flp-Recombinase Expression Vector (Thermo Fisher Scientific) for stable integration of GPCR-APEX into the genome. 24 hr after transfection, transfected cells were lifted using trypsin-EDTA (Corning) and plated into 10 cm culture dishes. 48 hr after transfection, stably transfected cells were selected by supplementing the medium with 100 mg/mL Hygromycin B Gold. After selection was complete, stable cell lines were grown to make frozen stocks in Bambanker (VWR).
Proximity labeling experiments
Frozen stable cell line stocks were recovered in 15 cm culture dishes with complete cell medium without Blasticidin until reaching sufficient density for passaging into 10 cm culture dishes. Upon 15%-20% confluency, cell medium was supplemented with 1 mg/mL doxycycline hyclate (Sigma Aldrich) to induce GPCR-APEX expression.
48 hr after doxycycline induction, cell medium was replaced with 10 mL of labeling medium (DMEM supplemented with 10% FBS, 10 mg/mL gentamicin, and 500 mM biotinyl tyramide purchased from Toronto Research Chemicals). All cells were incubated in labeling medium for 1 hr before adding hydrogen peroxide (H 2 O 2 ; Sigma Aldrich) to a final concentration of 1 mM. 30% (v/v) H 2 O 2 stock solution was freshly diluted to 1 M with Dulbecco's Phosphate Buffered Saline (DPBS) immediately before each experiment. Ligands were added to the cell medium and incubated for the indicated length of time. In all cases, exposure to H 2 O 2 was fixed to a 1 min labeling interval. For example, 40 s ligand incubation means the ligand was added to the cell medium 20 s after adding H 2 O 2 while 80 s ligand incubation means the ligand was added 20 s before adding H 2 O 2 . For all labeling experiments, H 2 O 2 was added to 1 mM final concentration. Immediately after adding H 2 O 2 /ligand, the culture dish was rocked several times to mix. Angiotensin II, Losartan, TRV027, and BI167107 were added to final concentrations of 100 nM, 100 nM, 500 nM, and 100 nM, respectively. In each case, these values are well in excess of ligand binding K D in order to ensure receptor saturation.
Exactly 1 min after H 2 O 2 treatment, the labeling medium was decanted and cells were washed three times with quenching solution (DPBS supplemented with 10 mM sodium ascorbate, 5 mM trolox, and 10 mM sodium azide). Following washing, cells were resuspended repeatedly with quenching solution containing 5 mM EDTA. After cells were harvested by centrifugation, quenching solution was aspirated and the pellet was flash-frozen and stored at À80 C until streptavidin pull-down.
AT1R-APEX and b2AR-APEX radioligand binding assay To measure receptor expression levels for AT1R-APEX and b2AR-APEX during proximity labeling experiments, stable cell lines used for the proximity labeling experiment were seeded on 10 cm plates, cultured, and doxycycline-induced in the conditions used for proximity labeling experiments. Cells were washed in PBS and subsequently harvested by incubating with PBS with 0.05% EDTA, pH 7.4, for 10 min at 4 C. Cells were collected and centrifuged at 1000 x RPM for 5 min and re-suspended in assay buffer (20 mM HEPES, 100 mM NaCl, pH 7.4). AT1R-APEX expression was assayed using radioligand binding using 50 nM [ 3 H]-olmesartan. Binding reactions were conducted in assay buffer with 1 mg/mL bovine serum albumin (Rockland), pH 7.4. Specific binding was determined by subtracting non-specific binding (10 mM candesartan) from total binding (assay buffer). Reactions were incubated for 90 min at room temperature and subsequently washed (50 mM Tris, pH 7.4) and captured on GF-B glass fiber filters using a Brandel harvester (Brandel). b2AR-APEX expression level was assayed using [
3 H]-dihydroalprenolol at 10 nM and 10 mM propranolol was used to measure non-specific binding by same procedure. Protein concentrations were measured using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific).
AT1R-APEX ERK signaling assay
Expi293F HEK293 cells (Thermo Fisher Scientific) (10 mL) stably expressing pcDNA6⁄TR (Thermo Fisher Scientific) were transiently transfected and enhanced following the manufacturer's protocol with pcDNA-AT1R-WT or AT1R-APEX under the control of a TETinducible promoter. Receptor expression was induced 48 hr after transfection by addition of 5 mM sodium butyrate and 4 mg/mL doxycycline. To induce AT1R activation and downstream ERK phosphorylation, 24 hr post-transfection cells were left untreated (control) or treated with 10 mM angiotensin II. At the indicated time following angiotensin II stimulation, 200 mL of cells were removed and cell lysed by the addition of 200 mL 2x Laemmli buffer. Cell lysates were sonicated for 20 s and remaining cell debris was pelleted at 14,000 3 RPM for 15 min. Cell lysates were subject to SDS-PAGE and levels of phosphorylated ERK (p44/42, Thr202/Tyr204) and total cellular ERK (tERK) were determined by traditional western blotting techniques using anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (Cell Signaling Technology) and anti-MAP Kinase 1/2 (Erk1/2) Antibody (EMD Millipore).
AT1R-APEX internalization assay b-arrestin-dependent internalization of WT AT1R and AT1R-APEX was measured as described previously (Strachan et al., 2014) using the activated GPCR endocytosis assay (DiscoveRx), based on complementation of b-galactosidase ''Enzyme Acceptor'' and ''ProLink'' fragments. Briefly, U2OS cells with stably integrated Enzyme Acceptor-tagged b-arrestin 2 and an endosome-localized ProLink tag were transfected transiently with N-terminal Flag-tagged WT AT1R or AT1R-APEX constructs. Transfections were performed using FuGENE 6 (Promega) using a 1:5 ratio of DNA/transfection reagent. One day post-transfection, cells were seeded into 96-well plates at a density of 35,000 cells/well using AssayComplete Cell Plating 5 Reagent. Two days post-transfection, cells were stimulated with a serial dilution of angiotensin II for 3 hr at 37 C and then treated with PathHunter detection reagents. After an additional 1 hr incubation at room temperature, luminescence was detected using a NOVOstar microplate reader (BMG Labtech).
b2AR-APEX signaling assay
Signaling assays for b2AR-APEX and b2AR WT were performed as described previously with some modifications (Liberles and Buck, 2006) . HEK293T (ATCC) cells were seeded in 96-well plates to achieve 70%-80% confluency on the day of transfection. Each well was transfected with 20 ng each of a pcDNA5 encoding b2AR-APEX/b2AR WT and CRE-SEAP reporter plasmid (BD Biosciences). Transfection was performed using Lipofectamine 2000 (Thermo Fisher Scientific) following manufacturer's instructions. After incubation of the cells with the transfection mixture and serum-free media for 5 hr at 37 C, transfection mixtures were aspirated and replaced with fresh DMEM with 4.5 g/L glucose and L-glutamine, no pyruvate (VWR), supplemented with 10 mg/mL Gentamicin (VWR). Then transfected cells were treated with indicated final concentrations of isoproterenol (Sigma Aldrich) and incubated at 37 C for 48 hr followed by 2 hr of incubation at 70 C. Supernatant from each well was mixed with an equal volume of 0.12 mM 4-methylumbelliferyl phosphate (Sigma Aldrich) in 2 M diethanolamine bicarbonate (diethanolamine from Alfa Aesar diluted in Milli-Q and supplemented with dry ice), pH 10, and incubated for 9 min at room temperature. Lastly, the fluorescence was measured using EnVision 2103 Multilabel Reader (PerkinElmer).
LMBRD2 Knockdown assay
HEK293T cells (ATCC) were seeded in 15 cm plates to achieve 50%-60% confluency on the day of first transfection. Each plate was transfected with either Silencer Select LMBRD2 siRNA (Thermo Fisher Scientific) or AllStars Negative Control siRNA (QIAGEN) using Lipofectamine RNAiMAX (Thermo Fisher Scientific) according to manufacturer's protocol. The final siRNA concentration was 25 nM in both cases. 24 hr after siRNA transfection, cells were trypsinized and seeded in 96-well plates to achieve 70%-80% confluency on the following day. Then each well was transfected with plasmid encoding WT b2AR and agonist-treated as described above for b2AR-APEX signaling assay. Transfected cells were incubated for 24 hr after agonist-treatment and were assayed for fluorescence measurement (72 hr after siRNA transfection). The difference in Log(EC 50 ) values was assessed by an unpaired two-sided Student's t test.
For qPCR, cells transfected with siRNA was harvested using RNeasy Mini Kit (QIAGEN) according to manufacturer's protocol. Extracted RNA was reverse-transcribed using SuperScript II Reverse Transcriptase (Thermo Fisher Scientific) with Random Primers (Thermo Fisher Scientific). Resulting cDNA was mixed with PowerUp SYBR Green Master Mix (Thermo Fisher Scientific) and either ACTB or LMBRD2 qPCR primers (Eurofins Genomics). qPCR was performed and analyzed using QuantStudio 6 Flex Real-Time PCR System (Thermo Fisher Scientific).
Streptavidin pull-down of biotinylated proteins All stock solutions and buffers used for streptavidin pull-down experiments were prepared freshly and filtered through 0.22 mm filters. Frozen cells were lysed with lysis solution (2 M sodium hydroxide with 7.5% 2-mercaptoethanol in Milli-Q water) and left on ice for 15 min. Lysates were pipetted repeatedly to ensure complete cell lysis. For subsequent TCA precipitation, an equal volume of icecold 55% trichloroacetic acid (TCA) was added followed by incubation on ice for 15 min.
Proteins were precipitated by centrifugation at 21,130 3 g at 4 C for 10 min. The pellet was washed with À20 C cold acetone, vortexed, and centrifuged at 21,130 3 g at 4 C for 10 min using a tabletop centrifuge. Following centrifugation, acetone was aspirated and the pellet was acetone-washed again three more times. After the last washing step, re-suspension buffer (8 M urea, 100 mM sodium phosphate pH 8, 100 mM NH 4 HCO 3 , 1% SDS (w/v), 10 mM TCEP in Milli-Q water titrated to pH 7 with NaOH) was added to the pellets. Tubes containing pellets and re-suspension buffer were sonicated in a Bioruptor sonifier bath (Diagenode) with 3 cycles for 30 s each, 100% duty cycle, highest power setting. Samples were then vortexed for 1 hr at room temperature to completely re-suspend proteins and allow for reduction of proteins by TCEP. Pellet dissolvation and alkaline pH of the solution was checked afterward.
Re-suspended proteins were centrifuged at 21,130 3 g at room temperature for 10 min and the clear supernatant was transferred into new microcentrifuge tubes. Freshly prepared 400 mM iodoacetamide stock solution in 50 mM ammonium bicarbonate was added to the supernatant to a final concentration of 20 mM, immediately vortexed, and incubated in the dark for 25 min at room temperature. After alkylation, freshly prepared dithiothreitol stock solution was added to 50 mM final concentration to quench alkylation. Water was added to each sample to reach final concentrations of 4 M urea and 0.5% (w/v) of SDS.
A 75 mL suspension equivalent per sample of streptavidin magnetic beads (Thermo Fisher Scientific) was washed twice with 4 M urea, 0.5% SDS (w/v), 100 mM sodium phosphate pH 8 and was added to each sample and tubes were rotated overnight at 4 C. Aliquots containing 5% of proteins in re-suspension buffer of each sample were saved prior to pull-down and 1.5% of total (inputs) were subjected to SDS-PAGE and western blotting analysis with StreptActin-HRP conjugate (Bio-Rad) to assess biotinylation of inputs. Following streptavidin pull-down, magnetic beads were washed three times with 4 M urea, 0.5% SDS (w/v), 100 mM sodium phosphate pH 8, and three times with the same buffer without SDS to avoid interference of SDS with downstream mass spectrometry analysis. Beads were transferred to fresh tubes after the first washing step.
Western blotting analysis of biotinylated proteins Samples of cell lysates saved after TCA-precipitation and re-suspension (inputs) were analyzed by western blotting. After standard SDS-PAGE, proteins were transferred to nitrocellulose membranes and stained with Ponceau S (Sigma Aldrich) prior to blocking to monitor equal protein loading. Membranes were blocked with 4% (w/v) non-fat milk powder in TBST (0.1% Tween-20 in Tris-buffered saline) at room temperature for 2 hr. Blocked membranes were incubated with StreptActin-HRP conjugate (Bio-Rad) diluted 1:50,000 in TBST with 4% non-fat milk powder overnight at 4 C with constant shaking. Prior to chemiluminescent detection, blots were washed with TBST four times, 5 min each time. Western blots were developed using Amersham ECL Western Blotting Detection Kit (GE Healthcare).
On-bead digestion and TMT labeling All liquid reagents used were HPLC quality grade. Washed beads were re-suspended in 50 mL of freshly prepared and filtered 2 M Urea, 50 mM ammonium bicarbonate, 8% acetonitrile (v/v) with 1 mL of LysC stock solution (2 mg/ml, Wako), vortexed briefly and incubated at 37 C for 3 hr. Samples were then diluted 1:4 with 50 mM ammonium bicarbonate to lower the concentration of urea to 0.5 M and trypsin stock (Promega) was added 1:200 (v/v). After mixing, digests were continued for at least 6 hr at 37 C or overnight and beads were magnetically removed. Digests were acidified with trifluoroacetic acid (TFA) and peptides were desalted and purified by C 18 solid phase extraction. Peptides dried in a vacuum centrifuge (SpeedVac) to completion were re-suspended in 200 mM HEPES pH 8.5, 30% acetonitrile (v/v) and labeled with TMT 10-plex reagents (Thermo Fisher Scientific) for 1 hr. Reactions were quenched with hydroxylamine at a final concentration of 0.3% (v/v) for 15 min and 1% of labeled peptides were analyzed for efficiency of label incorporation and relative ratios by mass spectrometry.
Labeled and quenched peptides were pooled and 10% of the pool was separated to obtain unfractionated samples and samples were dried to near completion in a speed vac. Samples were re-suspended in water and acidified with TFA. Fractionation of labeled peptides was done by high pH reversed phase (Thermo Fisher Scientific). After loading of labeled peptides onto pre-conditioned columns and a single wash with water, excess unincorporated TMT label was removed by washing reverse phase columns once with 0.1% trimethylamine (TEA) buffer containing 5% acetonitrile. Samples were fractionated under alkaline conditions into 12 fractions with increasing concentrations of acetonitrile: 10%, 12.5%, 15%, 17.5%, 20%, 25%, 30%, 35%, 40%, 50%, 65% and 80%. Fractions 1 and 7, 2 and 8, 3 and 9, 4 and 10, 5 and 11, 6 and 12 were pooled to obtain 6 final pooled fractions for subsequent analysis. Pooled fractions and the unfractionated sample were dried to completion and further purified and desalted by acidic C 18 solid phase extraction (StageTip). For the unfractionated sample, unincorporated TMT reagents were removed by an additional washing step with 5% acetonitrile (v/v) and 1% formic acid (v/v) after peptide binding. Labeled peptides were finally re-suspended in 5% formic acid (v/v) and 5% acetonitrile (v/v). All measurements were performed in duplicate and repeated in three independent experiments. Errors shown as means ± SEM.
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